Leony Antoun

BMI body mass index BTC biliary tract cancers CCA cholangiocarcinoma, cTNM tumour stage dCCA distal cholangiocarcinoma DFS disease-free survival dMMR/MSI deficient mismatch repair/microsatellite instability eCCA extrahepatic cholangiocarcinoma ECOG PS Eastern Cooperative Oncology Group performance status EGFR Epidermal Growth Factor Receptor EO early onset EOBTC Early onset biliary tract cancers ESCAT ESMO Scale for Clinical Actionability of Molecular Targets GBC gallbladder cancers iCCA...

1. Introduction Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, especially in Asian countries but also in Europe and the United States [1]. With a slight male predominance [2], this cancer is the third leading cause of cancer-related death in Western countries [1,3]. Only 20–30% of patients are diagnosed with resectable or borderline resectable tumors. In these patients, even with the adjuvant FOLFIRINOX, less than 30% are cured [4].

There is so far no international consensus concerning the prescription of antithrombotic agents in hemodialysis patients. It is not clear yet why they cause more bleeding in some patients and are beneficial in others. We therefore tried to find out what triggers bleeding in this population. This is an observational before-and-after study that included all patients undergoing hemodialysis in our center between 2005 and 2015.